title: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
abstract: From July, 1980, to June, 1983, 319 patients with newly diagnosed metastatic prostatic cancer were randomized to one of three treatment protocols: diethylstilbestrol (DES) or bilateral orchiectomy, cyclophosphamide plus 5-fluorouracil plus DES, and estramustine phosphate (Emcyt). Ninety-three per cent of 296 patients were eligible for evaluation. This report shows no difference in survival, disease-free progression time, or status regarding pain at entry. Other prognostic factors failed to reveal any difference within any of the treatment protocols.
mesh_terms: D001792:Blood Platelets / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000494:pharmacology / Q000627:therapeutic use*; D004961:Estramustine / Q000494:pharmacology / Q000627:therapeutic use*; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011897:Random Allocation
chemical_list: D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D004054:Diethylstilbestrol; D003520:Cyclophosphamide; D005472:Fluorouracil